Is­rael's Te­va puts for­eign­er in line for CEO's job; Ver­tex wins ex­pand­ed la­bel for Ka­ly­de­co

→ Is­rael’s Te­va is re­port­ed­ly tak­ing a hard look at a for­eign­er for its next CEO, spark­ing a pa­tri­ot­ic row.

→ The FDA has ap­proved Ver­tex’s Ka­ly­de­co for use in peo­ple with cys­tic fi­bro­sis (CF) ages 2 and old­er who have one of 23 resid­ual func­tion mu­ta­tions in the cys­tic fi­bro­sis trans­mem­brane con­duc­tance reg­u­la­tor (CFTR) gene. As a re­sult, the Boston biotech bumped up its rev­enue pro­jec­tions for the year to $770 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.